Telehealth as Drug Storefront
Ro and the telehealth capital cycle
Free consults turned telehealth into a drug storefront, not a visit business. Ro and Hims removed the awkward office trip, gave patients a simple intake form and clinician review, then made money when the prescription was filled and refilled each month. That model scaled fast because generic sildenafil was cheap, high margin, and easy to ship, unlike traditional telehealth players such as Teladoc that sold the visit itself to employers and insurers.
-
The key unlock was workflow simplicity. ED usually needed a lightweight async consult, not ongoing labs or in person follow up, so one digital flow could cover intake, prescribing, payment, and fulfillment inside a single app experience.
-
The tradeoff was weak retention. Because generic Viagra and Cialis became broadly available, the product was easy to copy and easy for patients to switch away from, which helped drive yearly churn around 50% for Ro and Hims in the ED era.
-
That is why later categories mattered so much. More complex treatments like GLP-1s and testosterone require dose changes, labs, monitoring, and coaching, which creates a stickier subscription and gives the platform more room to charge for care, not just pills.
The model is heading toward conditions where the software, clinician workflow, and follow up matter more than the initial prescription. As commodity generics get price competed away, the winners in telehealth will be the companies that turn one click medication demand into recurring care programs with higher retention and higher revenue per patient.